Clinical Trials
15 trialsNCT06463665 2026-06-04
VIRO-25
Genelux Corporation
Phase 2 Recruiting
NCT05063565 2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2 Active not recruiting
NCT06551142 2026-05-22
PanTumor-101
GlaxoSmithKline
Phase 1 Recruiting
NCT05303532 2026-05-19
ROSY-D
AstraZeneca
Phase 3 Enrolling by invitation
NCT06606847 2026-05-15
LADOGA
AstraZeneca
Phase 2 Active not recruiting
NCT03837899 2026-04-21
Durvalumab and Tremelimumab for Pediatric Malignancies
AstraZeneca
Phase 1/2 Active not recruiting
NCT05941897 2026-03-05
LOTOS
AstraZeneca
Phase 2 Active not recruiting
NCT03822351 2024-10-08
COAST
MedImmune LLC
Phase 2 Completed
NCT03946800 2024-10-02
A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors
MedImmune LLC
Phase 1 Completed
NCT02291055 2023-03-20
A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer
Advaxis, Inc.
Phase 1/2 Terminated
NCT03162224 2022-08-25
Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
MedImmune LLC
Phase 1/2 Completed
NCT03794544 2022-02-24
Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
MedImmune LLC
Phase 2 Completed
NCT02423863 2020-12-17
Poly-ICLC
Oncovir, Inc.
Phase 2 Completed
NCT02705482 2019-08-26
A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors
MedImmune LLC
Phase 1 Completed
NCT02556463 2018-12-19
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
MedImmune LLC
Phase 1 Terminated